DeepMed Research

Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Clinical Trials

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Phase 4

Not yet recruiting

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)
Sudden Cardiac Death
Ventricular Arrhythmia
Implantable Cardioverter Defibrillator (ICD)
Beta-blocker Therapy
Cardiomyopathy

Interventions: Drug: Metoprolol Succinate
Drug: Carvedilol

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: University of Rochester

Target Recruit Count: 2000

Registration Number: NCT06964464

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

Phase 1

Recruiting

Conditions: TBI Traumatic Brain Injury

Interventions: Drug: control
Drug: propranolol
Drug: Carvedilol

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-02

Lead Sponsor: Mansoura University

Target Recruit Count: 100

Registration Number: NCT06836856

Locations: 🇪🇬
Zagazig University Hospitals, Zagazig,, Zagazig, Egypt
🇪🇬
Zagazig University Hospitals, Zagazig, Egypt

CARPEUS : Effect of Carvedilol on the Portosystemic Gradient As Measured by Endoscopic Ultrasound

Not Applicable

Not yet recruiting

Conditions: Cirrhosis
Portal Hypertension Related to Cirrhosis

Interventions: Drug: Carvedilol

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 30

Registration Number: NCT06861075

Locations: 🇫🇷
Lise Laclautre, Clermont-Ferrand, France

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer
HER2+ Breast Cancer

Interventions: Drug: Carvedilol
Drug: Empagliflozin

First Posted Date: 2025-02-25

Last Posted Date: 2025-04-22

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 40

Registration Number: NCT06844669

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Carvedilol and Alverine in Portal Hypertension

Phase 2

Not yet recruiting

Conditions: Hypertension, Portal

Interventions: Drug: Carvedilol and alverine

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 30

Registration Number: NCT06696248

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Early Phase 1

Recruiting

Conditions: Leukemia
Hematopoetic Stem Cell Transplantation
Donor Lymphocyte Infusion
CAR T-Cell Therapy
Lymphoma
Cell Therapy

Interventions: Behavioral: Exercise
Drug: Placebo
Drug: Isoproterenol
Drug: Bisoprolol Fumarate Tablet 10 mg
Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Drug: Carvedilol 50 mg
Drug: Roflumilast 500 Mcg Oral Tablet

First Posted Date: 2024-10-16

Last Posted Date: 2024-10-16

Lead Sponsor: University of Arizona

Target Recruit Count: 100

Registration Number: NCT06643221

Locations: 🇺🇸
The University of Arizona, Tucson, Arizona, United States

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

Phase 4

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)
Esophageal Varices

Interventions: Procedure: Endoscopic variceal ligation
Drug: Carvedilol

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-13

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 120

Registration Number: NCT06594744

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders

Phase 4

Recruiting

Conditions: Cirrhosis
Esophageal Varices

Interventions: Other: Carvedilol plus endoscopic variceal ligation
Drug: Carvedilol alone

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-11

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 80

Registration Number: NCT06594783

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism

Not Applicable

Not yet recruiting

Conditions: Drug Interaction

Interventions: Drug: Caffeine Tablet
Drug: Bupropion Hydrochloride Capsels
Drug: Repaglinide Capsels
Drug: Flurbiprofen Capsels
Drug: Omeprazole 10 MG
Drug: Dextromethorphan Oral Solution
Drug: Midazolam oral solution
Drug: Simvastatin tablets
Drug: Placebo
Drug: Carvedilol
Drug: Diclofenac

First Posted Date: 2024-08-22

Last Posted Date: 2024-08-22

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 12

Registration Number: NCT06566794

Locations: 🇫🇮
Department of Clinical Pharmacology, Helsinki, Finland

The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis

Phase 2

Not yet recruiting

Conditions: Hypertension, Portal

Interventions: Drug: Alverine
Drug: Carvedilol

First Posted Date: 2024-06-24

Last Posted Date: 2024-06-24

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 178

Registration Number: NCT06470386

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy